Welcome to our dedicated page for Context Therapeutics news (Ticker: CNTX), a resource for investors and traders seeking the latest updates and insights on Context Therapeutics stock.
Context Therapeutics Inc. reports developments as a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors. Its news centers on oncology programs including CTIM-76, a CLDN6 x CD3 bispecific antibody; CT-95, a MSLN x CD3 bispecific antibody; and CT-202, a Nectin-4 x CD3 bispecific antibody.
Recurring updates cover clinical and preclinical data, regulatory designations, scientific conference presentations, operating results, research and development spending, liquidity, investor-conference activity and equity-based employee inducement grants. CTIM-76 has received FDA Fast Track designation for platinum-resistant ovarian cancer, adding regulatory status to the company's solid-tumor development disclosures.
Context Therapeutics (Nasdaq:CNTX) will present at the Jefferies Global Healthcare Conference in New York on June 3, 2026, at 7:35 a.m. ET, with a live webcast and 90-day replay on its investor website.
Context also granted a Nasdaq Rule 5635(c)(4) inducement stock option for 146,000 shares to a new employee, priced at $2.63 per share, with a 10-year term and four-year vesting schedule.
Context Therapeutics (Nasdaq:CNTX) amended its exclusive license with BioAtla for CT-202, its Nectin-4 x CD3 T cell engager. The amendment converts the license into a fully paid-up, non-terminable agreement, eliminating all future CT-202 milestones and royalties in exchange for $4.5 million upfront and a final $2.0 million payment due by August 1, 2026. Phase 1 initiation for the CT-202 trial is expected in the third quarter of 2026.
Context Therapeutics (Nasdaq: CNTX) reported Q1 2026 results and pipeline milestones. Cash and cash equivalents were $54.5 million as of March 31, 2026, expected to fund operations into mid-2027. Phase 1a interim data for CTIM-76 expected June 2026 and for CT-95 expected September 2026. CT-202 first-in-human initiation is anticipated in Q3 2026 after Australian HREC and TGA CTN acknowledgements. FDA granted Fast Track Designation to CTIM-76 in April 2026. Q1 R&D expense was $7.0 million; net loss was $8.7 million.
Neogen (NASDAQ:NEOG) appointed Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary effective immediately. Ms. Stacey brings more than 25 years of life sciences legal and compliance experience, including over 10 years as a public company chief legal officer and 5 years as a public company board member.
She previously served at Galera Therapeutics and held senior legal roles at Wistar Institute, Antares Pharma, FXI, Auxilium, and Aventis Behring. Ms. Stacey also serves on the board of Context Therapeutics (NASDAQ:CNTX).
Context Therapeutics (Nasdaq: CNTX) announced that the FDA granted Fast Track Designation to CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, for treatment of platinum-resistant ovarian cancer (PROC).
CTIM-76 is in a Phase 1 trial evaluating safety, tolerability, pharmacokinetics and anti-tumor activity in CLDN6-positive advanced or metastatic ovarian, endometrial and testicular cancers. The company expects interim Phase 1a data in June 2026.
Context Therapeutics (Nasdaq: CNTX) reported full-year 2025 results and pipeline updates. The company had $66.0 million cash at December 31, 2025, and expects runway into mid-2027. CTIM-76 Phase 1a interim data expected June 2026; CT-95 Phase 1a interim data expected September 2026. CT-202 regulatory filings completed and first patient dosing expected in Q3 2026. 2025 R&D expense was $31.9M and net loss was $36.1M.
Context Therapeutics (Nasdaq: CNTX) announced a poster presentation at the American Association for Cancer Research Annual Meeting 2026, April 17-22 in San Diego. The poster will present preclinical data on CT-202, a Nectin-4 x CD3 T cell engaging bispecific antibody for solid tumors.
The poster (Abstract #5392) is scheduled for Tuesday, April 21, 2026, 9:00 a.m.–12:00 p.m. PT in Poster Section 48, Session PO.CL05.12. According to the company, the poster will be available on its Publications page at the start of the session.
Context Therapeutics (Nasdaq: CNTX) will participate in multiple investor conferences in February–March 2026, presenting at Guggenheim, TD Cowen, Citizens, and Leerink events.
Presentations, fireside chats, and 1x1 meetings are scheduled; a live webcast will be available on the company's News and Events page with replays for 90 days.
Context Therapeutics (Nasdaq:CNTX) granted non-qualified stock options totaling 120,000 shares to two new employees as inducement awards under Nasdaq Listing Rule 5635(c)(4).
The options were granted on hire dates (January 1, 2026 and January 12, 2026) with exercise prices equal to the Nasdaq closing prices on those dates ($1.47 and $1.49). Each option has a 10-year term and vests over four years: 25% after one year and the remainder in 36 equal monthly installments, subject to continued service.
Context Therapeutics (Nasdaq: CNTX) presented posters on its CT-95 and CT-202 bispecific T cell engager programs at the SITC 40th Annual Meeting (Nov 7–9, 2025).
CT-95 (mesothelin x CD3) is avidity enhanced and affinity tuned; as of the Oct 30, 2025 cutoff the Phase 1 trial has enrolled 6 patients and is dosing Cohort 3 (priming 0.18 µg/kg, full dose 0.6 µg/kg). No cytokine release syndrome > Grade 2, no dose limiting toxicities, and no MTD reached; initial Phase 1a data is anticipated in mid-2026.
CT-202 (nectin-4 x CD3) shows potent preclinical activity with favorable PK/safety and the company expects to complete regulatory filings to support a first-in-human trial in Q2 2026. Presentation materials will be posted in the company’s Publications and Posters section.